Revenue
1 million USD
2025 Q3 · USD
Exact inputs and evidence
- Revenue: 1000000 USD Source
Fundies. English
APPLIED THERAPEUTICS, INC.
EDGARAnnual consolidated revenue for 2024: about USD 455K, using the latest reported figures. The previous period, 2023, was about USD 9.993M.
Latest quarter
Operating margin
-1,675.8%
2025 Q3 · %
Operating cash flow
-18.4 million USD
2025 Q3 · USD
- Cash and cash equivalents
- 11.9 million USD Source
Exact value
11900000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 144 million shares Source
Exact value
144300674 shares
Reported share-count change
24.02% · 27.9 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
1 million USD
2024-10-01 – 2025-09-30
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-02-03.
Financial data available through: 2024-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2024-12-31
- Operating income: 2 of 11 periods available· newest 2024-12-31
- Net income: 2 of 11 periods available· newest 2024-12-31
- Operating cash flow: 2 of 11 periods available· newest 2024-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 2 of 11 periods available· newest 2024-12-31
- Total liabilities: 2 of 11 periods available· newest 2024-12-31
- Current assets: 2 of 11 periods available· newest 2024-12-31
- Current liabilities: 2 of 11 periods available· newest 2024-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2024-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2024-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
-95.4%Prior period
USD 9.99 million
–
Current period
USD 455,000
–
Exact inputs and evidence
455000 − 9993000 = -9538000 USD
9993000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source455000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 14.14 millionPrior period
−USD 119.76 million
–
Current period
−USD 105.62 million
–
Exact inputs and evidence
-105624000 − -119763000 = 14139000 USD
-119763000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source-105624000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 29.13 millionPrior period
−USD 55.17 million
–
Current period
−USD 84.31 million
–
Exact inputs and evidence
-84305000 − -55173000 = -29132000 USD
-55173000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source-84305000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2024 2024-01-01 – 2024-12-31
- Revenue USD 455,000 100% of revenue
- Operating costs Derived USD 104.75 million 23,023% of revenue
- Operating income −USD 104.3 million −22,923% of revenue
- Tax, interest and other Derived USD 1.33 million 291% of revenue
- Net income −USD 105.62 million −23,214% of revenue
Cash
- Operating cash flow −USD 84.31 million −18,529% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2023 Operating loss: operating costs were 746% of revenue.
- 2024 Operating loss: operating costs were 23,023% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | 9993000 | 74528000 Derived | -64535000 | 55228000 Derived | -119763000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 455000 | 104754000 Derived | -104299000 | 1325000 Derived | -105624000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 455K 2024
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Revenue | 9993000 |
|
| 2024 | Revenue | 455000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
-95.4% 2024
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Year over year | No prior comparable period |
|
| 2024 | Year over year | -95.4% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -22,922.9% 2024
Net margin -23,214.1% 2024
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Operating margin | -645.8% |
|
| 2024 | Operating margin | -22,922.9% |
|
| 2023 | Net margin | -1,198.5% |
|
| 2024 | Net margin | -23,214.1% |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -84.3M 2024
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Operating cash flow | -55173000 |
|
| 2024 | Operating cash flow | -84305000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
34.2% 2024
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Liabilities / assets | 131.3% |
|
| 2024 | Liabilities / assets | 34.2% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
3.06× 2024
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Current assets / current liabilities | 0.76× |
|
| 2024 | Current assets / current liabilities | 3.06× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 119.76 million Exact valueExact value: -119763000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 55.17 million Exact valueExact value: -55173000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 105.62 million Exact valueExact value: -105624000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 84.31 million Exact valueExact value: -84305000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
38 filings · 2,496 latest values · 2,496 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001697532, 1697532, APLT, edgar:1697532
Also known as APPLIED THERAPEUTICS, INC., Applied Therapeutics Inc., Applied Therapeutics, Inc., Applied Therapeutics, Inc.